Novartis has entered a significant partnership with Arrowhead Pharmaceuticals, investing $200 million upfront to license and develop RNA interference (RNAi) therapies targeting Parkinson’s disease and other synucleinopathies. This multi-asset deal focuses on Arrowhead’s preclinical siRNA candidate, ARO-SNCA, designed to silence alpha-synuclein, a key protein involved in neurodegenerative disease pathology. The collaboration leverages Arrowhead’s Targeted RNAi Molecule (TRiM) platform, which enables subcutaneous administration and penetration across the blood-brain barrier, addressing prior delivery challenges in central nervous system therapies. Novartis aims to transform the treatment landscape for neurodegenerative diseases with this novel modality, while Arrowhead continues to expand its discovery pipeline through strategic partnerships with multiple global pharma companies. This agreement underscores the growing importance of RNA-based therapeutics in addressing complex neurological disorders and reflects strong confidence in innovative delivery technologies driving clinical advancement.